Atricure Inc (ATRC)

AtriCure, Inc. (NASDAQ:ATRC) Short Interest Down 6.9% in April - MarketBeat

MarketBeat

AtriCure (ATRC): Moving Average Crossover Alert - Yahoo News UK

Yahoo News UK

AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference - Business Wire

Business Wire

AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Singapore News

Yahoo Singapore News

AtriCure Enhances Governance and Expands Stock Plan - TipRanks.com - TipRanks

TipRanks

AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session - Yahoo Movies UK

Yahoo Movies UK

AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session - Yahoo New Zealand News

Yahoo New Zealand News

AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session - Yahoo Singapore News

Yahoo Singapore News

TimesSquare Capital Management LLC Purchases 71,275 Shares of AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat

MarketBeat

AtriCure (NASDAQ:ATRC) lifts 9.3% this week, taking five-year gains to 96% - Yahoo Movies UK

Yahoo Movies UK

Global Ablation Devices Market to grow at a CAGR of 11.65% by 2030, Evaluates DelveInsight - openPR

openPR

Needham & Company LLC Lowers AtriCure (NASDAQ:ATRC) Price Target to $40.00 - Defense World

Defense World

Canaccord Genuity Group Trims AtriCure (NASDAQ:ATRC) Target Price to $49.00 - Defense World

Defense World

AtriCure (NASDAQ:ATRC) Given New $34.00 Price Target at JPMorgan Chase & Co. - Defense World

Defense World

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Movies UK

Yahoo Movies UK

AtriCure (NASDAQ:ATRC) Stock Price Up 6.7% - MarketBeat

MarketBeat

Justin J. Noznesky Sells 1500 Shares of AtriCure, Inc. (NASDAQ:ATRC) Stock - Defense World

Defense World

AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Defense World

AtriCure executive sells shares worth over $36,000 - Investing.com ZA - Investing.com South Africa

Investing.com South Africa

Justin J. Noznesky Sells 1,500 Shares of AtriCure, Inc. (NASDAQ:ATRC) Stock - MarketBeat

MarketBeat

AtriCure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Yahoo Finance

AtriCure executive sells shares worth over $36000 - Investing.com India

Investing.com India

AtriCure shares target cut $7, maintains Buy rating - Investing.com India

Investing.com India

Canaccord Genuity cuts AtriCure shares target despite strong Q1 - Investing.com India

Investing.com India

AtriCure shares target cut by $6, maintains buy rating - Investing.com India

Investing.com India

New York State Common Retirement Fund Buys 30280 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World

Defense World

AtriCure shares target cut $7, maintains Buy rating By Investing.com - Investing.com UK

Investing.com UK

Canaccord Genuity cuts AtriCure shares target despite strong Q1 - Investing.com

Investing.com

Cracking The Code: Understanding Analyst Reviews For AtriCure

Benzinga

Earnings call: AtriCure reports robust Q1 2024 growth, reaffirms guidance - Investing.com

Investing.com

AtriCure shares target cut by $6, maintains buy rating - Investing.com UK

Investing.com UK

AtriCure Inc (ATRC) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Strategic Innovations ... - GuruFocus.com

GuruFocus.com

AtriCure (NASDAQ:ATRC) Given New $49.00 Price Target at Canaccord Genuity Group - MarketBeat

MarketBeat

Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics

Zacks Investment Research

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Canada Finance

Yahoo Canada Finance

AtriCure Reports First Quarter 2024 Financial Results - Business Wire

Business Wire

AtriCure Inc (ATRC) Surpasses Revenue Estimates in Q1 2024 Despite Wider Losses - Yahoo Finance Australia

Yahoo Finance Australia

AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference - Business Wire

Business Wire

AtriCure (NASDAQ:ATRC) Upgraded by Oppenheimer to Outperform - Defense World

Defense World

Objective long/short (ATRC) Report - Stock Traders Daily

Stock Traders Daily

AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management

Zacks Investment Research

First Week of June 21st Options Trading For AtriCure (ATRC) - Nasdaq

Nasdaq

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management - Yahoo Finance

Yahoo Finance

Key Takeaways From AtriCure Analyst Ratings

Benzinga

Key Takeaways From AtriCure Analyst Ratings - AtriCure (NASDAQ:ATRC) - Benzinga

Benzinga

Revolutionizing Atrial Fibrillation Treatment: The Robotic Convergent Plus Procedure - Cureus

Cureus

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump - Simply Wall St

Simply Wall St

AtriCure is top co-op employer for UC biomedical engineering students - University of Cincinnati

University of Cincinnati

AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference - Business Wire

Business Wire

AtriCure (ATRC) Declined due to Concerns Over Anti-Obesity Drug - Yahoo Finance

Yahoo Finance